Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

JAMA Network - In this issue of JAMA Oncology, Diefenhardt and colleagues1 report a post hoc analysis of the previously published German CAO/ARO/AIO-04 trial2 and found that...

  • Invited commentary highlights new data on adherence to neoadjuvant chemoradiation for rectal cancer & outcome, raising question of whether this association represents correlation or causation when assessing retrospective data https://t.co/S1qseHGTWm #GICSM #CRCSM

JAMA Network - A variation on chimeric antigen receptor (CAR) T-cell therapy that instead modifies natural killer (NK) immune cells appeared to be safe and effective in...

  • In a phase 1 and 2 trial, HLA-mismatched anti-CD19 CAR-NK cells derived from cord blood led to a response in 8 of 11 patients with relapsed or refractory CD19-positive cancers (non-Hodgkin’s lymphoma or chronic lymphocytic leukemia [CLL]) https://t.co/m3YPxQ0Db4

JAMA Network - This post hoc analysis of a randomized phase 3 trial analyzes the association of treatment adherence with disease-free survival among patients with rectal cancer...

  • Treatment compliance to neoadjuvant 5-FU chemoradiotherapy with or without #Oxaliplatin is associated with clinical outcome in rectal #cancer whereas treatment compliance to adjuvant #chemotherapy is not https://t.co/f1vZcGdIT6

JAMA Network - This Patient Page describes the use of circulating tumor DNA testing to detect cancer-associated genetic variations and guide treatment...